📈
📈 Business
Moderna's pivot to cancer treatment lifts stock 177%
After its fortunes cratered when demand for Covid-19 vaccines plummeted, Moderna has been reinventing itself as a cancer company. The pivot to oncology has driven the company's stock up 177%. Moderna had been working on mRNA-based cancer therapies throughout the Covid vaccine era.
Similar stories
Comments
No comments yet
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!